China News Online, November 12 (Chen Jingjiang Yizhou Wang Guangzhao) The top international academic journal "Cell Metabolism" published on the 12th the research results of Professor Shao Zhimin's team at Fudan University Cancer Hospital.
The study is the first internationally based on multidimensional omics big data to analyze the metabolic characteristics of the "most refractory breast cancer"-triple-negative breast cancer, revealing new targets and bringing new hope for patients to obtain precise treatment as soon as possible.
It is reported that in recent days, Shao Zhimin’s team has achieved three consecutive research breakthroughs. In addition to publishing in the international authoritative journal Cell Metabolism, these research results have also been published in Nature Communications and the Journal of the National Cancer Institute.
The research team took the lead in drawing a gene mutation map of breast cancer in thousands of people in China, showing the most common mutation genes and mutation frequencies of breast cancer in the Chinese population.
Photo courtesy of Fudan University Cancer Hospital
It is reported that "triple-negative breast cancer" has always been a difficult problem that the medical community is trying to overcome.
In 2019, Shao Zhimin's team drew a multi-omics map of the global triple-negative breast cancer cohort. Such a large-scale map has not been reported before.
According to different genetic characteristics, the researchers first proposed the "Fudan classification" standard, that is, triple-negative breast cancer is divided into four different subtypes such as immunomodulatory type, combined with further genetic testing, to provide accurate plans for effective treatment.
On the basis of this research, the team carried out FUTURE "umbrella" clinical research, through the precise "Fudan classification", selected suitable treatment options for patients in a targeted manner, and greatly improved the efficacy of refractory breast cancer patients.
Professor Shao Zhimin said in an interview on the 12th that different types of tumors or different subtypes of the same tumor have obvious differences in metabolic characteristics.
Through a large amount of data comparison and analysis, the researchers found that the metabolic characteristics of triple-negative breast cancer are quite different in different samples.
Shao Zhimin said that different subtypes of triple-negative breast cancer have different sensitivity to different types of treatment options.
The new targets revealed by the research are expected to allow patients to receive precise treatment as soon as possible.
It is reported that the gene mutation map is the most basic "reference index" for precise breast cancer treatment.
During the interview, the reporter learned that previously, the maps used for breast cancer treatment were data from Western countries, and the map of breast cancer gene mutations in the Chinese National People's Congress was "blank".
From the genetic level, the research team revealed the unique characteristics of breast cancer in China, and screened 484 genes that are highly related to personalized breast cancer treatment plans, basically covering all mutant genes that have been announced at home and abroad, forming a precise detection "catalog".
The research results are published in well-known academic journals.
Photo courtesy of Fudan University Cancer Hospital
Based on this, the research team took the lead in drawing a map of breast cancer gene mutations in thousands of people in China, showing the most common mutation genes and mutation frequencies of breast cancer in the Chinese population.
A single-center Chinese population breast cancer gene mutation map of this size has not been reported before.
Professor Shao Zhimin said that the study provides a good foundation for comprehensively exploring the targets of precision treatment of breast cancer in the Chinese population and successfully applying them in clinical practice.
It is reported that this result was published in the internationally renowned academic journal "Nature Communications".
During the interview, the reporter learned that germline gene mutations are gene mutations that occur in genetic cells.
In all breast cancers, triple-negative breast cancer has different germline gene mutation profiles, and there are ethnic differences.
Professor Shao Zhimin said frankly that before, the germline gene mutations and their clinical significance of Chinese triple-negative breast cancer patients were still unclear, which made precision treatment "cloudy".
The study found that 16% of triple-negative breast cancer patients have at least one pathogenic or possibly pathogenic germline gene mutation; compared with Caucasian or African American patients, the proportion of RAD51D germline gene mutations in Chinese breast cancer patients is higher. high.
Professor Shao Zhimin said that the relevant comprehensive analysis and research results are conducive to more precise clinical interventions for patients, and it is expected that the precise treatment of triple-negative breast cancer will be "yunkaiwusan".
The internationally renowned journal, the National Cancer Research Center Journal of the United States, published the research results jointly completed by Shao Zhimin's team and the Shanghai Pasteur Institute of the Chinese Academy of Sciences.
(Finish)